1. Home
  2. STK vs COLL Comparison

STK vs COLL Comparison

Compare STK & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Columbia Seligman Premium Technology Growth Fund Inc

STK

Columbia Seligman Premium Technology Growth Fund Inc

N/A

Current Price

$46.36

Market Cap

921.0M

Sector

Finance

ML Signal

N/A

Logo Collegium Pharmaceutical Inc.

COLL

Collegium Pharmaceutical Inc.

N/A

Current Price

$25.76

Market Cap

752.3M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
STK
COLL
Founded
N/A
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
921.0M
752.3M
IPO Year
2009
2015

Fundamental Metrics

Financial Performance
Metric
STK
COLL
Price
$46.36
$25.76
Analyst Decision
Buy
Analyst Count
0
8
Target Price
N/A
★ $44.00
AVG Volume (30 Days)
48.9K
★ 546.2K
Earning Date
01-01-0001
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
★ 0.64
Revenue
N/A
★ $780,567,000.00
Revenue This Year
N/A
$6.59
Revenue Next Year
N/A
$1.89
P/E Ratio
★ N/A
$39.98
Revenue Growth
N/A
N/A
52 Week Low
$32.50
$21.43
52 Week High
$58.46
$50.79

Technical Indicators

Market Signals
Indicator
STK
COLL
Relative Strength Index (RSI) 34.31 67.29
Support Level $38.43 $25.47
Resistance Level $53.92 $26.39
Average True Range (ATR) 1.86 0.89
MACD -0.40 0.17
Stochastic Oscillator 6.35 79.94

Price Performance

Historical Comparison
STK
COLL

About STK Columbia Seligman Premium Technology Growth Fund Inc

Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.

Share on Social Networks: